U.S. markets closed
  • S&P 500

    4,111.08
    -25.40 (-0.61%)
     
  • Dow 30

    33,891.02
    -34.99 (-0.10%)
     
  • Nasdaq

    11,887.45
    -119.50 (-1.00%)
     
  • Russell 2000

    1,957.72
    -27.82 (-1.40%)
     
  • Crude Oil

    74.43
    +0.32 (+0.43%)
     
  • Gold

    1,880.60
    +1.10 (+0.06%)
     
  • Silver

    22.30
    +0.06 (+0.26%)
     
  • EUR/USD

    1.0730
    -0.0067 (-0.62%)
     
  • 10-Yr Bond

    3.6340
    +0.1020 (+2.89%)
     
  • GBP/USD

    1.2025
    -0.0032 (-0.26%)
     
  • USD/JPY

    132.6600
    +1.5100 (+1.15%)
     
  • BTC-USD

    22,804.92
    -165.09 (-0.72%)
     
  • CMC Crypto 200

    527.84
    +2.70 (+0.51%)
     
  • FTSE 100

    7,836.71
    -65.09 (-0.82%)
     
  • Nikkei 225

    27,693.65
    +184.19 (+0.67%)
     

KRTL Holding Group Inc Welcomes Dr. Malcolm A. Leissring as Chief Science Officer of KRTL Biotech, Inc.

Lakewood, CO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) is pleased to announce its wholly owned subsidiary, KRTL Biotech, Inc., an international research, and development company, has appointed Dr. Malcolm A. Leissring as its founding Chief Science Officer.  "I am honored to be a part of this vibrant team of experts with such complementary expertise.  The future indeed looks very bright for us," said Dr. Leissring.

Dr. Leissring is an internationally recognized neuroscientist with expertise in the molecular pathogenesis of Alzheimer 's disease and diabetes, along with extensive expertise in drug discovery and drug development.  He holds an A.B. degree from the UC Berkeley, an M.A. from San Francisco State University, and a Ph.D. from UC Irvine.  He conducted his postdoctoral training at Harvard Medical School under the mentorship of Dr. Dennis Selkoe, who is widely considered to be one of the leading Alzheimer's disease researchers in the world.

Dr. Leissring has held faculty positions at Harvard Medical School, The Scripps Research Institute, and Mayo Clinic, and currently runs his laboratory within the Institute for Memory Impairments and Neurological Disorders at UC Irvine (UCI MIND).  His academic achievements include the publication of more than 60 scientific publications in top-tier journals such as Nature, Neuron, and the Proceedings of the National Academy of sciences, and he has been awarded numerous grants from the National Institutes of Health, the Alzheimer's Association, the American Diabetes Association among others.

Dr. Leissring pioneered the development of the first potent and selective inhibitors of insulin-degrading enzyme, which have demonstrated utility for the treatment of diabetes (Maianti et al., Nature 2014) and wound healing (Suire et al., PLoS ONE 2018). Dr. Leissring has received awards from many prestigious organizations, including the Alzheimer’s Association, the American Diabetes Association, the Ellison Medical Foundation, and the American Federation for Aging Research.

About KRTL Holding Group, Inc.

We are a holding company interested in diversifying risk and accessing new markets. The Company operates its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp., with precision and excellence and continues to create and strengthen the KRTL reputation.  This allows KRTL Holding Group, Inc. to capitalize on any range of investment opportunities.  Our organization values collaboration and emphasizes a transparent work environment. Additional information on KRTL is available online at  www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACT: KRTL Holding Group, Inc. Main 800-707-0586 info@krtlholding.com